Incyte Corp (INCY)
73.13
-0.06
(-0.08%)
USD |
NASDAQ |
Jan 08, 16:00
73.13
0.00 (0.00%)
After-Hours: 20:00
Incyte SG&A Expense (Quarterly): 309.20M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Exelixis Inc | 111.80M |
| Merck & Co Inc | 2.731B |
| Pfizer Inc | 3.244B |
| Biomarin Pharmaceutical Inc | 253.50M |
| Insmed Inc | 118.93M |